InvestorsHub Logo
Post# of 180666
Next 10
Followers 2
Posts 88
Boards Moderated 0
Alias Born 10/03/2018

Re: Volcano post# 113357

Tuesday, 12/11/2018 10:32:08 AM

Tuesday, December 11, 2018 10:32:08 AM

Post# of 180666
"Vivos Inc. has obtained an exclusive license to eight (8) patents related to RadioGel™ device technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and Vivos announced in February 2011. The Agreement grants Vivos an exclusive license to make, have made, use and sell RadioGel™ as a device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost."




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News